|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM261968327 |
| 003 |
DE-627 |
| 005 |
20250220083931.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.06.008
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0873.xml
|
| 035 |
|
|
|a (DE-627)NLM261968327
|
| 035 |
|
|
|a (NLM)27368805
|
| 035 |
|
|
|a (PII)S1521-6616(16)30114-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kustiawan, Iwan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Inactivated pepsin inhibits neutrophil activation by Fcgamma-receptor-dependent and independent stimuli
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2017
|
| 500 |
|
|
|a Date Revised 13.08.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Pepsin is widely used to produce F(ab')2 fragments of immunoglobulin G (IgG). In many cases, at least part of the pepsin will remain present in the F(ab')2 preparation, albeit in (irreversibly) inactivated form. Here we report on a potent immunomodulatory effect of irreversibly inactivated pepsin on activated human neutrophils. Degranulation, induced by coated IgG or via cytochalasin B/N-formyl-Met-Leu-Phe, was measured by quantifying elastase release, and was found to be inhibited in a dose-dependent manner by inactivated pepsin. Since a number of intravenous immunoglobulin (IVIg) products are also treated by limited digestion with pepsin, we investigated if pepsin would be present in quantities large enough to inhibit neutrophil activation. The amounts of pepsin detected in three different pepsin-treated IVIg products were found to be too low to induce an effect, at least in an in vitro setting
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Immunomodulation
|
| 650 |
|
4 |
|a Intravenous immunoglobulin (IVIg)
|
| 650 |
|
4 |
|a Neutrophil
|
| 650 |
|
4 |
|a Pepsin
|
| 650 |
|
7 |
|a FCGR1A protein, human
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin Fab Fragments
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 650 |
|
7 |
|a Receptors, IgG
|2 NLM
|
| 650 |
|
7 |
|a Cytochalasin B
|2 NLM
|
| 650 |
|
7 |
|a 3CHI920QS7
|2 NLM
|
| 650 |
|
7 |
|a N-Formylmethionine Leucyl-Phenylalanine
|2 NLM
|
| 650 |
|
7 |
|a 59880-97-6
|2 NLM
|
| 650 |
|
7 |
|a Leukocyte Elastase
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.37
|2 NLM
|
| 650 |
|
7 |
|a Pepsin A
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.23.1
|2 NLM
|
| 700 |
1 |
|
|a Derksen, Ninotska
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rispens, Theo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 169(2016) vom: 01. Aug., Seite 85-88
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:169
|g year:2016
|g day:01
|g month:08
|g pages:85-88
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.06.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 169
|j 2016
|b 01
|c 08
|h 85-88
|